Talquetamab is a first-in-class BsAb targeting G protein-coupled receptor class C group 5 member D (GPRC5D) and CD3, redirecting T-cells to eliminate MM cells independently of BCMA expression.127,128. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.